With recent estimates predicting the global market for stem cells and stem cell products reaching almost $6.6-billion by 2016, the research continues. Companies like StemCells, Inc., Aastrom Biosciences, Inc., BioTime, Inc., International Stem Cell Corp. and Advanced Cell Technology among many others are hard at work in the sector trying to solve the roadblocks that keep the FDA from approving any stem cell treatment to date.
Meanwhile, Nuvilex, a biotech headquartered in Silver Spring, Maryland, is currently in negotiations with biotechnology and pharmaceutical entities that wish to examine the employment of Nuvilex's living cell encapsulation technology, or Cell-in-a-Box(TM), in the development of treatments for various diseases that would utilize stem cells.
What is Cell-in-a-Box? Could this living cell encapsulation technology be the silver bullet to get many stem cell companies through some of the roadblocks that have plagued their success?